• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion

    2022-08-10 01:39:34HaiFengQinFanJunShiChaoYangZhangDaWeiLuoShiYueQinJingWuHaiXieJingTingZhangQingHuaQiuKunLiuGuoTongXuGuoXuXuJingFaZhang
    關(guān)鍵詞:勺子護(hù)患戲曲

    INTRODUCTION

    Retinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy,resulting in visual impairment. The incidence of RVO is about 0.5%-1.8% in the general population

    . The complications due to RVO include macular edema (RVO-ME), retinal neovascularization with secondary vitreous hemorrhage,neovascular glaucoma,

    ., which largely impaired the vision of patients. The pathogenesis of RVO-ME is multifactorial.The occluded and damaged blood vessels as well as retinal ischemia can result in local hypoxia with the increased hypoxia inducible factor-1 alpha (HIF-1α), resulting in elevated secretion of vascular endothelial growth factor(VEGF), which could cause vascular hyperpermeability and neovascularization

    . Anti-VEGF treatment has been shown to be beneficial to patients with RVO-ME and becomes the first-line therapy in the treatment of RVO-ME

    . Besides VEGF, other factors including inflammatory cells and cytokines were also associated with the pathogenesis of RVO-ME.

    During the clinical practice, we noticed that the RVOME patients with HRF benefit from anti-VEGF injections,demonstrating the improved visual acuity (VA), reduced central macular thickness (CMT) and HRF number, as well as the decreased non-perfusion area (NPA). Besides the direct anti-VEGF effect, we hypothesized that anti-VEGF reagents might exert anti-inflammatory effect in patients with RVOME. To address this question, we retrospectively reviewed 28 eyes from 28 treatment-na?ve patients, who underwent three consecutive intravitreal injections of anti-VEGF reagents.The VA, CMT, the HRF number, and NPA size before and after intravitreal injections were quantified and compared.

    Increasing evidence suggested that hyperreflective foci(HRF) in retina were identified as the active inflammatory cells, especially microglia and macrophages, by using optical coherence tomography (OCT) or optical coherence tomography angiography (OCTA), indicating the inflammatory conditions in retina for patient with RVO-ME. HRF were first mentioned by Coscas

    in patients with age-related macular degeneration (AMD) with spectral-domain OCT. Subsequently,HRF have been involved in many retinal diseases, such as RVO, diabetic retinopathy, choroideremia, and other retinal degenerative diseases

    . Although its pathogenesis is still debated, HRF likely characterizes a progressive nature of an inflammatory retinal microenvironment.

    The intravitreal injection was conducted at the temporal limbus through the eyeball’s pars plana under aseptic conditions in the operating room. Twenty-eight patients received three consecutive intravitreal injections of ranibizumab at the concentration of 0.5 mg/ 0.05 mL (Novartis Pharma Stein AG, Switzerland,

    =18) or conbercept at the concentration of 0.5 mg/ 0.05 mL(Chengdu Kang Hong Biotech Co., Ltd., Sichuan Province,China,

    =10) with a 30-gauge needle. Each injection interval allowed a variation of 1wk. The participants were treated with three monthly intravitreal injections until the macular edema(ME) was resolved.

    1.1 臨床資料 收集2011年1—11月我院門診血清TPPA、RPR均陽(yáng)性需要治療的梅毒患者824例,其中男446例,女378例。男性平均年齡45.8歲,女性平均年齡37.9歲。

    SUBJECTS AND METHODS

    This study was approved by the Clinical Research Ethical Committee of Shanghai General Hospital affiliated to Shanghai Jiao Tong University (Permits No.2020KY205-2) and adhered to the principles of the Declaration of Helsinki. Informed consents were signed by all the participants.

    The present study was a retrospective cohort study,including 28 treatment-na?ve patients, aged 64.2±2.1 years old. The patients were comprised of 14 males (50%) and 14 females (50%). The RVO included 14 BRVO and 14 CRVO.This retrospective study was conducted in the Department of Ophthalmology, Shanghai General Hospital affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai, China between August 26, 2019, and July 30,2020. Participants who received intravitreal injections of anti-VEGF drugs for three months were included in the study. The eyes with any co-existing ocular diseases, including diabetic retinopathy, hypertensive retinopathy, AMD, or uveitis,

    .,were excluded.

    At the initial examination, comprehensive ophthalmic examinations were performed for every patient, including OCTA, fundus photography, best-corrected visual acuity(BCVA), intraocular pressure and anterior segment evaluation using slit-lamp biomicroscopy. Follow-up examinations were conducted 1wk after each intravitreal injection.

    由于種子千粒重低籽粒瘦弱,幼苗頂土能力差,為了保證全苗,在播前精細(xì)整地,足墑下種,適當(dāng)淺播,深3厘米左右。

    Retinal microvasculature was visualized by using the RTVue XR Avanti OCT system (Optovue, Inc., Fremont, CA, USA),and the quantification was carried out using the manufacturer’s AngioVue software. The scanning was centered on the fovea with an area of 6×6 mm

    .

    CMT measured with OCTA was calculated as the average retinal thickness in a 1-mm-diameter circular region centered at the fovea which was automatically analyzed by OCTA.

    To observe the efficacy of two different anti-VEGF reagents,we sub-grouped the patients and analyzed the effect based on ranibizumab and conbercept injections. In Table 2, for ranibizumab treatment, the VA increased in RVO (1.4±0.1

    0.6±0.1,

    =18,

    <0.05), BRVO (1.2±0.2

    0.3±0.1,

    =8,

    <0.05), and CRVO (1.6±0.2

    0.9±0.2,

    =10,

    <0.05);and for conbercept treatment, the VA was increased in RVO(1.7±0.2

    1.0±0.1,

    =10,

    <0.05), BRVO (1.7±0.3

    0.8±0.2,

    =6,

    <0.05), and CRVO (1.7±0.1

    1.2±0.2,

    =4,

    <0.05).No significant difference has been found in term of VA improvement for each sub-group between ranibizumab and conbercept treatment.

    The NPA was outlined manually in enface image of the superficial capillary plexus (SCP) with 6×6 mm

    scanning area in OCTA and analyzed automatically with the OCTA auto-segmentation software. The SCP was segmented as 3 μm below the internal limiting membrane and 15 μm below the inner plexiform layer.

    The data were analyzed by using the IBM SPSS Statistics 21 software. All values are presented as a number or mean±standard deviation. The VA was expressed as the logarithm of the minimum angle of resolution (logMAR).A paired

    -test was employed to compare BCVA, the number of HRF, and NPA between the baseline and after 3 consecutive monthly anti-VEGF injections. A

    -value less than 0.05 was determined as statistically significant difference.

    RESULTS

    CMT is a sensitive parameter to evaluate RVO-ME. In our study, the CMT reduced significantly after anti-VEGF injections (Table 1 and Figure 2),RVO (460±34.0

    268.8±12.0 μm,

    =28,

    <0.05), BRVO(413±47

    255±11 μm,

    =14,

    <0.05), and CRVO (512±47

    283±22 μm,

    =14,

    <0.05).

    目前,隨著我國(guó)社會(huì)主義發(fā)展進(jìn)程的不斷推進(jìn),以電網(wǎng)改造工作為主的建設(shè)內(nèi)容逐漸被列為我國(guó)重要的議事日程當(dāng)中。且國(guó)家電網(wǎng)在智能電網(wǎng)戰(zhàn)略部署的督導(dǎo)作用下,形成重點(diǎn)加強(qiáng)區(qū)域電網(wǎng)建設(shè)、提高中低壓配電網(wǎng)智能化運(yùn)行水平的改造體系。另外,在先進(jìn)技術(shù)的協(xié)調(diào)作用下,我國(guó)終端遠(yuǎn)程通訊技術(shù)基本上得到進(jìn)一步優(yōu)化,利于提升農(nóng)網(wǎng)系統(tǒng)的自動(dòng)化建設(shè)水平。由此可以看出,實(shí)行電網(wǎng)改造工作對(duì)于我國(guó)電網(wǎng)建設(shè)進(jìn)程而言,具有多么重要的意義[1]。

    BCVA improved significantly from baseline to the final follow-up, and the mean change of BCVA was -0.8±0.1 for RVO group (Table 1). Figure 1 demonstrated the changes of VA before and after the treatment. After three consecutive injections of anti-VEGF reagents, the VA significantly increased in all three groups, RVO (1.5±0.1

    0.8±0.1,

    =28,

    <0.05), BRVO (1.4±0.2

    0.6±0.1,

    =14,

    <0.05), and CRVO (1.6±0.1

    1.0±0.2,

    =14,

    <0.05).

    3.1 建立良好的護(hù)患關(guān)系 良好的護(hù)患關(guān)系是醫(yī)護(hù)活動(dòng)順利開(kāi)展的必要條件,患者的依從性常與護(hù)患關(guān)系有著密切的聯(lián)系[6]。融洽的護(hù)患關(guān)系可產(chǎn)生良好的心理氣氛和情緒反應(yīng),促使患者遵循治療方案。如果護(hù)患間沒(méi)有充分的交流,沒(méi)有形成良好的信任關(guān)系,就難以促使患者建立良好的服藥依從性。因此,護(hù)士應(yīng)針對(duì)老年人的特點(diǎn),并結(jié)合其知識(shí)層次和性格,進(jìn)行有效的溝通交流,建立良好的護(hù)患關(guān)系。

    The HRF number was manually counted in the whole retina within a 6-mm diameter centered on the fovea using a foveaspanning horizontal B-scan. HRF in OCTA was defined as a discrete and well-circumscribed dot-shaped lesion of equal or higher reflectivity than the retinal pigment epithelium (PRE)band. The maximal diameter of HRF was limited within the 20 to 50 μm range in order to exclude small counting noise signals(less than 20 μm) and prevent large hyperreflective clumps,such as hard exudates. Poor-quality images with a signal strength index less than 4/10 were excluded. The quantification of HRF was conducted independently by two experienced physicians.

    The baseline clinical features of 28 eyes were shown in Table 1. The participants are comprised of 14 females (50%) and 14 males (50%). The mean age of patients was 64.2±2.1 years old, ranging from 50 to 78 years old, with 63.2±2.5 years old for BRVO and 64.8±3.4 years old for CRVO. The RVO included both BRVO (50%,

    =14)and CRVO (50%,

    =14). All participants underwent three consecutive monthly injections of ranibizumab (18 patients)or conbercept (10 patients). Eight patients with BRVO and 10 patients with CRVO were injected with ranibizumab; and 6 patients with BRVO and 4 patients with CRVO were injected with conbercept. The mean interval between baseline and final follow-up was 108.1±8.7 (range 56-240)d.

    For ranibizumab treatment group, the CMT decreased in RVO(506±38

    284±17 μm,

    =18,

    <0.05), and CRVO (578±46

    290±29 μm,

    =10,

    <0.05; Table 2). As for conbercept treatment groups, the CMT decreased in RVO (399±61

    242±12 μm,

    =10,

    <0.05; Table 2). No obvious difference for the reduction of CMT was observed for each sub-group between ranibizumab and conbercept treatment.

    中國(guó)教師:在大的格局和總體布局當(dāng)中,廣州以校際間均衡、區(qū)域間均衡為目標(biāo),以好教育為統(tǒng)領(lǐng),組合拳打得十分精彩,并得到了肯定。教育部《教育現(xiàn)代化進(jìn)程監(jiān)測(cè)評(píng)價(jià)指標(biāo)體系研究》專題組發(fā)布的《全國(guó)15個(gè)副省級(jí)城市教育現(xiàn)代化監(jiān)測(cè)評(píng)價(jià)與比較研究報(bào)告(2015)》顯示,在4個(gè)現(xiàn)代化一級(jí)監(jiān)測(cè)指標(biāo)中,廣州好幾個(gè)綜合排名位居前列,其中教育普及發(fā)展第二、教育條件保障第二、教育質(zhì)量要素第四。那么,接下來(lái)在辦好家門口的學(xué)校方面,有什么好的做法嗎?

    就拿最開(kāi)始的喂飯方式來(lái)講,正確的方式是把勺子平行地伸進(jìn)嘴巴,放在寶寶的舌頭上面,讓他自己把嘴唇閉住把食物從勺子上抿下來(lái)。而事實(shí)中,很多喂養(yǎng)者都急于把食物喂進(jìn)去,選擇的方式是更有“效率”地把勺子與嘴巴呈30度角,從上往下地把食物塞進(jìn)去,然后寶寶被動(dòng)地合上嘴巴。

    HRF was identified as active macrophages and/or microglia in retina on OCT or OCTA examination. In this study, HRF was shown to be distributed throughout the whole retina, especially in the inner retina. HRF number significantly reduced in RVO(76.5±4.8

    47.8±4.3,

    =28,

    <0.05), BRVO (68.1±5.6

    40.6±4.7,

    =14,

    <0.05), and CRVO (84.9±7.3

    55±6.9,

    =14,

    <0.05), respectively, following anti-VEGF treatment(Table 1 and Figure 3).

    For ranibizumab treatment, the number of HRF decreased in RVO (83.8±6.7

    55.8±5.8,

    =18,

    <0.05), and CRVO(90.7±9.3

    66.7±6.7,

    =10,

    <0.05; Table 2). As for conbercept treatment group, the number of HRF decreased in RVO (64.9±4.5

    33.0±2.2,

    =10,

    <0.05; Table 2). No significant difference for HRF reduction was detected among three groups between ranibizumab and conbercept treatments.

    NPA reflected the non-perfusion of retinal capillaries due to transient occlusion of leukocyte in retinal blood vessels or permanent dropout of retinal capillaries forming acellular capillaries. To see whether or not anti-VEGF reagent could reduce NPA, we compared the NPA before and after three consecutive injections. As shown in Table 1, there was slightly increase of NPA for CRVO (10.4±1.4 mm

    ) than BRVO (8.9±1.0 mm

    ), but no significant difference, in the defined macular region (6×6 mm

    ) at baseline. After anti-VEGF treatment, we observed gradual reduction of NPA after three consecutive injections in patients with RVO, 8.9±1.0 mm

    (baseline), 8.5±1.0 mm

    (after 1

    injection), 8.1±1.0 mm

    (after 2

    injection), and 7.4±1.0 mm

    (after 3

    injection), although no significant difference was observed (Figure 4).

    To see the effect of different anti-VEGF reagents on NPA, we analyzed and compared their effect on the changes of NPA.The data showed that, in ranibizumab and conbercept treatment group, NPA decreased in RVO, BRVO, and CRVO (Table 2)but with no significant difference. No obvious change was shown in NPA reduction between ranibizumab and conbercept treatments.

    DISCUSSION

    With an estimated 16 million patients worldwide, RVO become one of the most common retinal vascular diseases in adults

    . In our study, the VA improved and the CMT decreased significantly in patients with RVO-ME after anti-VEGF treatments. The HRF also decreased significantly,accompanied with progressive reduction of NPA after three consecutive anti-VEGF treatments. This study indicated that retinal inflammation might play a contributory role in the pathogenesis of RVO-ME.

    The pathogenesis of RVO-ME is complicated, in which ischemia and hypoxia plays essential roles in the formation of RVO-ME. Ischemia and hypoxia could stabilize HIF-1α and leads to elevated secretion of VEGF and other down-stream targets. In human, VEGF family contains five members,including VEGF-A (usually named as VEGF), VEGF-B,VEGF-C, VEGF-D, as well as placental growth factor (PGF).Both VEGF and PGF play important roles in the formation of ME through inducing the breakdown of blood-retinal barrier (BRB). Besides, the inflammation is considered as a key player in RVO. Previous studies reported that several inflammatory factors, other than VEGF and PGF, contributed to the pathogenesis of RVO-ME, including angiotensin II,interleukin (IL)-1β, IL-6, IL-8, basic fibroblast growth factor(bFGF), monocyte chemoattractant protein 1 (MCP-1), and PGF,

    . Through binding VEGF receptors (VEGFR) on endothelial cells, VEGF and PGF induced the up-regulation of intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, enhancing the leukocyte adhesion to the vessel wall,thus leading to leukostasis, retinal non-perfusion and BRB breakdown. Chronic inflammation will result in acellular capillaries, aggregating the retinal hypoxia. VEGF and PGF also facilitate the proliferation and activation of microglia and macrophage through VEGFR. The HRF on OCT or OCTA mainly refers to the inflammatory cells in retina, such as microglia and macrophages. These inflammatory cells,including leukocytes, will release pro-inflammatory factors,causing BRB breakdown, ME, neuronal damage, and visual deterioration

    .

    We hypothesized that anti-VEGF reagents, by antagonizing VEGF and/or PGF, blocked the activation of VEGFR both on endothelial cells and inflammatory cells (microglia,macrophage, and leukocyte,

    .), thus down-regulated adhesion molecules of endothelial cell and deactivated the inflammatory cells as well as the inflammatory factor release. In this way, the leukostasis was alleviated and NPA was improved,and the HRF also decreased by anti-VEGF treatment, indicating an anti-inflammatory effect of anti-VEGF reagents.

    Although no statistically significant difference was found,we observed the amelioration of NPA in patients with RVO after anti-VEGF treatment (Figure 4). The improved NPA might be due to transient adhesion of leukocyte to endothelial cells

    CD11b/ICAM-1 interaction, and anti-VEGF treatment disrupted the interaction between leukocyte and endothelial cells and re-opened the occluded capillaries.Thus we found the gradual improvement of NPA in patients with RVO after anti-VEGF therapy. But for some patients,the initial NPA cannot be identified easily due to massive,intensive hemorrhage obscured the direct observation of non-perfusion in retina. For some NPA caused by capillary dropout, it can be extrapolated that this non-perfusion cannot be alleviated due to the permanent capillary obliteration because anti-VEGF treatment cannot re-vascularize the NPA in a timely manner. So, the patients with RVO are suggested to initiate anti-VEGF treatment as soon as possible to decrease and eliminate the non-perfusion caused by early transient occlusion by leukocytes, and thus avoid permanent capillary dropout (acellular capillaries).There are still some shortcomings in the current research.First, the sample size of this clinical study was comparatively small, that may affect the comparisons. Second, the study was a short-term observation, which needs a long-term followup. Last, OCTA requires consistent cooperation from the patients, and small vibration might make it difficult to perform the comparison among different groups. Therefore, longterm evaluation of the efficacy of anti-VEGF reagents and large sample multi-center studies are needed in the treatment of RVO-ME. Besides OCTA, other multimodal ophthalmic imagings are required for evaluation of RVO-ME before and after the treatment.

    李漁(1611-1680),浙江金華府蘭溪人,初名仙侶,后改名漁,字謫凡,號(hào)笠翁。他是明末清初時(shí)期著名的文學(xué)家、戲劇家、戲劇理論家、美學(xué)家,一生中創(chuàng)作了大量的文學(xué)作品,包括戲曲、小說(shuō)、詩(shī)詞、曲賦等,其中成就最高的是戲曲,他的作品將擬話本小說(shuō)與戲曲藝術(shù)巧妙地融合為一個(gè)整體,創(chuàng)作出《笠翁傳奇十種》《無(wú)聲戲》《十二樓》等優(yōu)秀戲曲作品。

    懷揣著對(duì)鄉(xiāng)村教育摯愛(ài)的堅(jiān)定信念,她在泥濘的小路上往返于各村校之間。70多歲的老母親患上了嚴(yán)重的白內(nèi)障,需要做眼球摘除手術(shù),為了工作,她無(wú)法陪護(hù)在母親的病床前。孩子高考前,她亦沒(méi)有時(shí)間陪伴。

    In summary, retinal inflammation plays a critical role in RVO-ME. As detected with OCTA, besides macular edema,HRF and NPA were also observed. In the pathogenesis of RVO-ME, the retina was stressed under ischemia and hypoxia,which stabilized HIF-1α and increased the production of its down-stream targets, including VEGF, PGF, and VEGFR.Through binding VEGFR, VEGF/PGF enhanced the expression of adhesion molecules on endothelial cells, such as ICAM-1 and VCAM-1, which promoted leukostasis, leading to increased NPA

    and aggregating the retinal hypoxia.VEGF/PGF also promoted the activation of inflammatory cells

    activating VEGFR on above cells, which were observed as increased number of HRF on OCTA. The activated inflammatory cells, such as macrophage and microglia,increased production of the inflammatory factors, such as IL-1β and IL-6, and MCP-1, further aggravating BRB breakdown and macular edema. The increasing NPA and activation of inflammation constitute a vicious cycle in the pathogenesis of RVO-ME. Anti-VEGF treatments, by antagonizing VEGF and/or PGF, breakdown the vicious cycle and ameliorate the inflammation and retinal hypoxia, as proposed in Figure 5.However, the specific mechanisms for anti-VEGF therapy in the reduction of HRF and NPA warrant further investigation to fully elucidate the anti-inflammatory effect of anti-VEGF in RVO-ME treatment.

    ACKNOWLEDGEMENTS

    Supported by the National Natural Science Foundation of China (No.81970811; No.81970810;No.82171062); Domestic Science and Technology Cooperation Project of Shanghai Municipal Science and Technology Commission (No.21015800700).

    None;

    None;

    None;

    None;

    None;

    None;

    None;

    None;

    None;

    None;

    None;

    None;

    None.

    1 Klein R. The 15-year cumulative incidence of retinal vein occlusion.

    2008;126(4):513.

    2 Klein BEK, Meuer SM, Knudtson MD, Klein R. The relationship of optic disk cupping to retinal vein occlusion: the beaver dam eye study.

    2006;141(5):859-862.

    3 Pierru A, Girmens JF, Héron E, Paques M. Retinal vein occlusions.

    2017;40(8):696-705.

    4 Jonas JB, Monés J, Glacet-Bernard A, Coscas G. Retinal vein occlusions.

    2017;58:139-167.

    5 Miyagi S, Nishinaka A, Yamamoto T, Otsu W, Nakamura S, Shimazawa M, Kitaoka T, Hara H. Establishment of a pigmented murine model abundant with characteristics of retinal vein occlusion.

    2021;204:108441.

    6 Lin J, Gibbons A, Smiddy WE. Cost-utility of anti-vascular endothelial growth factor treatment for macular edema secondary to central retinal vein occlusion.

    2021;5(7):656-663.

    7 Light JG, Tian J, Wenick AS. Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-vascular endothelial growth factor therapy.

    2021;5(9):888-900.

    8 Chhablani J, Stewart M, Paulose R, Gallego-Pinazo R, Dolz-Marco R.Clinical characteristics and treatment outcomes of recurrent central retinal vein occlusions.

    2018;33(2):191-197.

    9 Coscas G, De Benedetto U, Coscas F, Li Calzi CI, Vismara S, Roudot-Thoraval F, Bandello F, Souied E. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for followup and prognosis in exudative age-related macular degeneration.

    2013;229(1):32-37.

    10 Ogino K, Murakami T, Tsujikawa A, Miyamoto K, Sakamoto A, Ota M, Yoshimura N. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion.

    2012;32(1):77-85.

    11 Vujosevic S, Torresin T, Bini S, Convento E, Pilotto E, Parrozzani R,Midena E. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.

    2017;95(5):464-471.

    12 Romano F, Arrigo A, MacLaren RE, Charbel Issa P, Birtel J, Bandello F, Battaglia Parodi M. Hyperreflective foci as a pathogenetic biomarker in choroideremia.

    2020;40(8):1634-1640.

    13 Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T.Retinal microglia: just bystander or target for therapy?

    2015;45:30-57.

    14 Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P,Kowalski JW, Nguyen H, Wong TY,. The prevalence of retinal vein occlusion: pooled data from population studies from the United States,Europe, Asia, and Australia.

    2010;117(2):313-319.e1.

    15 Hirabayashi K, Tanaka M, Imai A,

    . Development of a novel model of central retinal vascular occlusion and the therapeutic potential of the adrenomedullin-receptor activity-modifying protein 2 system.

    2019;189(2):449-466.

    16 Daruich A, Matet A, Moulin A,

    . Mechanisms of macular edema: beyond the surface.

    2018;63:20-68.

    17 Alizadeh E, Mammadzada P, André H. The different facades of retinal and choroidal endothelial cells in response to hypoxia.

    2018;19(12):E3846.

    18 Campochiaro PA. Seeing the light: new insights into the molecular pathogenesis of retinal diseases.

    2007;213(2):348-354.

    19 De Bats F, Gambrelle J, Feldman A, Mauget-Faysse M, Germain-Pastene M, Denis P. Role of intolerance to hypoxia in the occurrence of anterior bilateral ischaemic optic neuropathy at high altitude.

    2010;33(10):724-727.

    20 van Bergen T, Etienne I, Cunningham F, Moons L, Schlingemann RO,Feyen JHM, Stitt AW. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases.

    2019;69:116-136.

    21 Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the beaver dam eye study.

    2000;98:133-141; discussion 141-143.

    22 Rodrik-Outmezguine VS, Okaniwa M, Yao Z,

    . Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.

    2016;534(7606):272-276.

    23 de Smet MD. Insights into the physiopathology of inflammatory macular edema.

    2017;58:168-177.

    24 Noma H, Mimura T, Yasuda K, Shimura M. Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema.

    2015;56(2):1122-1128.

    25 Jung SH, Kim KA, Sohn SW, Yang SJ. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion.

    2014;55(4):2290-2296.

    猜你喜歡
    勺子護(hù)患戲曲
    戲曲其實(shí)真的挺帥的
    做木勺子
    吃面
    青海湖(2020年6期)2020-09-07 08:08:22
    用一生詮釋對(duì)戲曲的愛(ài)
    海峽姐妹(2018年9期)2018-10-17 01:42:44
    七把勺子的故事
    論戲曲批評(píng)的“非戲曲化”傾向
    戲曲研究(2017年3期)2018-01-23 02:50:39
    護(hù)患情境會(huì)話
    護(hù)患情境會(huì)話
    護(hù)患情境會(huì)話
    護(hù)患情境會(huì)話
    久久亚洲精品不卡| 午夜福利视频在线观看免费| 90打野战视频偷拍视频| 亚洲国产精品一区三区| 国产精品成人在线| 一边摸一边做爽爽视频免费| 精品福利永久在线观看| 丝袜喷水一区| 曰老女人黄片| 国内毛片毛片毛片毛片毛片| 丝瓜视频免费看黄片| 黑人欧美特级aaaaaa片| 国产一区二区三区av在线| videosex国产| 不卡av一区二区三区| 中文字幕最新亚洲高清| 99香蕉大伊视频| 99精国产麻豆久久婷婷| 欧美老熟妇乱子伦牲交| 日韩欧美国产一区二区入口| 国产成人一区二区三区免费视频网站| 国产91精品成人一区二区三区 | 亚洲欧洲精品一区二区精品久久久| 午夜福利免费观看在线| 亚洲三区欧美一区| 性少妇av在线| 亚洲黑人精品在线| 美女高潮到喷水免费观看| av在线app专区| 亚洲精品国产av成人精品| 国产人伦9x9x在线观看| 女警被强在线播放| 亚洲精品中文字幕一二三四区 | 精品人妻一区二区三区麻豆| 免费日韩欧美在线观看| av一本久久久久| 午夜老司机福利片| 电影成人av| 99国产精品免费福利视频| 欧美av亚洲av综合av国产av| 国产无遮挡羞羞视频在线观看| 热re99久久国产66热| 大码成人一级视频| 后天国语完整版免费观看| 男女免费视频国产| 人妻一区二区av| 国产一卡二卡三卡精品| 蜜桃国产av成人99| 黑人操中国人逼视频| 一级片'在线观看视频| tocl精华| 国产成人精品久久二区二区91| 高清视频免费观看一区二区| 日韩电影二区| 在线亚洲精品国产二区图片欧美| 亚洲国产精品成人久久小说| 中文字幕高清在线视频| 多毛熟女@视频| 亚洲成国产人片在线观看| 嫁个100分男人电影在线观看| 女人久久www免费人成看片| 两个人免费观看高清视频| 午夜精品国产一区二区电影| 九色亚洲精品在线播放| 国产成人免费无遮挡视频| svipshipincom国产片| 99久久精品国产亚洲精品| 亚洲欧美精品自产自拍| 久久久久精品人妻al黑| 女人高潮潮喷娇喘18禁视频| 一边摸一边抽搐一进一出视频| 国产日韩一区二区三区精品不卡| 日本wwww免费看| 国产精品久久久久久人妻精品电影 | 新久久久久国产一级毛片| 欧美日韩国产mv在线观看视频| 黑人欧美特级aaaaaa片| 久久国产精品大桥未久av| 天天影视国产精品| 我要看黄色一级片免费的| 久久热在线av| 欧美一级毛片孕妇| 美女主播在线视频| 最近最新免费中文字幕在线| 深夜精品福利| 国产日韩欧美亚洲二区| av免费在线观看网站| 无限看片的www在线观看| 成人18禁高潮啪啪吃奶动态图| 青草久久国产| 90打野战视频偷拍视频| 国产精品久久久人人做人人爽| 亚洲精品一区蜜桃| 麻豆乱淫一区二区| 超碰成人久久| 50天的宝宝边吃奶边哭怎么回事| 欧美少妇被猛烈插入视频| 夜夜夜夜夜久久久久| 久久天躁狠狠躁夜夜2o2o| 美女脱内裤让男人舔精品视频| 人人妻人人爽人人添夜夜欢视频| 乱人伦中国视频| 建设人人有责人人尽责人人享有的| 欧美精品啪啪一区二区三区 | 看免费av毛片| 高清av免费在线| 两人在一起打扑克的视频| 如日韩欧美国产精品一区二区三区| 中文字幕人妻丝袜一区二区| 97在线人人人人妻| a 毛片基地| 欧美精品高潮呻吟av久久| 黄色视频在线播放观看不卡| 亚洲av男天堂| 精品国产国语对白av| 成人国产av品久久久| 久久国产精品男人的天堂亚洲| 热re99久久精品国产66热6| 亚洲自偷自拍图片 自拍| 亚洲成人手机| 久久人人爽av亚洲精品天堂| 欧美成狂野欧美在线观看| 日韩三级视频一区二区三区| 亚洲精品久久成人aⅴ小说| 国产xxxxx性猛交| 亚洲国产精品999| 免费在线观看完整版高清| 精品亚洲成a人片在线观看| 丝袜脚勾引网站| 国产成人精品久久二区二区免费| 午夜成年电影在线免费观看| 十分钟在线观看高清视频www| 亚洲熟女精品中文字幕| 国产成人精品久久二区二区91| 成在线人永久免费视频| 亚洲男人天堂网一区| 免费黄频网站在线观看国产| 日本五十路高清| 亚洲精品一区蜜桃| 天天躁夜夜躁狠狠躁躁| 12—13女人毛片做爰片一| 亚洲三区欧美一区| 国产老妇伦熟女老妇高清| 免费在线观看视频国产中文字幕亚洲 | 成人国产av品久久久| 极品少妇高潮喷水抽搐| 女人被躁到高潮嗷嗷叫费观| 国产亚洲一区二区精品| 侵犯人妻中文字幕一二三四区| 99国产精品一区二区三区| 男男h啪啪无遮挡| 日日摸夜夜添夜夜添小说| 中文字幕最新亚洲高清| 日本猛色少妇xxxxx猛交久久| 成人手机av| 免费看十八禁软件| 永久免费av网站大全| 亚洲精品中文字幕一二三四区 | 久久精品国产亚洲av香蕉五月 | 久久免费观看电影| 大香蕉久久成人网| 午夜福利在线观看吧| 亚洲av欧美aⅴ国产| 成年美女黄网站色视频大全免费| 性高湖久久久久久久久免费观看| 19禁男女啪啪无遮挡网站| 国产三级黄色录像| 人人妻人人澡人人爽人人夜夜| 亚洲av日韩精品久久久久久密| 久久久久精品人妻al黑| 亚洲久久久国产精品| 十八禁网站网址无遮挡| 国产精品九九99| 国产免费现黄频在线看| 国产免费现黄频在线看| 最近中文字幕2019免费版| 精品国产一区二区三区久久久樱花| 国产精品av久久久久免费| 亚洲欧美一区二区三区黑人| 欧美日韩亚洲综合一区二区三区_| 成人亚洲精品一区在线观看| 人人妻人人爽人人添夜夜欢视频| a级片在线免费高清观看视频| 热99久久久久精品小说推荐| 国产91精品成人一区二区三区 | 每晚都被弄得嗷嗷叫到高潮| 五月天丁香电影| 日本vs欧美在线观看视频| 亚洲九九香蕉| 捣出白浆h1v1| 热99久久久久精品小说推荐| 国产欧美日韩一区二区三 | 欧美日本中文国产一区发布| 国产欧美日韩精品亚洲av| 国产欧美日韩一区二区三 | 亚洲男人天堂网一区| 欧美在线黄色| tube8黄色片| 亚洲精品久久成人aⅴ小说| 丝袜喷水一区| 免费在线观看视频国产中文字幕亚洲 | 午夜福利影视在线免费观看| 国产免费视频播放在线视频| 久久久久久久精品精品| 精品国内亚洲2022精品成人 | 真人做人爱边吃奶动态| 欧美 亚洲 国产 日韩一| 日韩一区二区三区影片| 亚洲精品国产区一区二| 黄色 视频免费看| 91成人精品电影| 亚洲九九香蕉| 中文字幕人妻熟女乱码| 国产成人一区二区三区免费视频网站| 波多野结衣一区麻豆| 久久精品久久久久久噜噜老黄| 99精品久久久久人妻精品| 亚洲欧美成人综合另类久久久| 欧美日韩福利视频一区二区| 亚洲av男天堂| 欧美一级毛片孕妇| 黑人欧美特级aaaaaa片| 一级毛片女人18水好多| 亚洲专区字幕在线| 在线 av 中文字幕| 亚洲成人免费电影在线观看| 999精品在线视频| 人人妻,人人澡人人爽秒播| 天天影视国产精品| 1024香蕉在线观看| 深夜精品福利| 亚洲av电影在线进入| 免费观看人在逋| 性色av乱码一区二区三区2| 久久精品成人免费网站| av福利片在线| 一级片'在线观看视频| 91老司机精品| 男人爽女人下面视频在线观看| 超碰97精品在线观看| 女人高潮潮喷娇喘18禁视频| 国产麻豆69| 久久人人97超碰香蕉20202| 国产一区有黄有色的免费视频| h视频一区二区三区| 国产一卡二卡三卡精品| 深夜精品福利| 精品免费久久久久久久清纯 | 午夜久久久在线观看| 免费在线观看日本一区| 一本综合久久免费| a 毛片基地| 12—13女人毛片做爰片一| 国产亚洲精品第一综合不卡| 午夜福利乱码中文字幕| 日韩,欧美,国产一区二区三区| 久久国产精品大桥未久av| 久久天躁狠狠躁夜夜2o2o| 人人妻人人澡人人看| 国产区一区二久久| 黄色a级毛片大全视频| 一边摸一边做爽爽视频免费| 超碰成人久久| 热re99久久精品国产66热6| 亚洲欧美色中文字幕在线| 亚洲成av片中文字幕在线观看| 成在线人永久免费视频| 亚洲av欧美aⅴ国产| 久9热在线精品视频| 99久久精品国产亚洲精品| av又黄又爽大尺度在线免费看| 中国国产av一级| 亚洲精品国产av成人精品| 一区二区三区激情视频| 在线观看人妻少妇| 美女高潮到喷水免费观看| cao死你这个sao货| 大香蕉久久成人网| 亚洲国产欧美在线一区| 亚洲 欧美一区二区三区| 日韩 亚洲 欧美在线| 97在线人人人人妻| 在线精品无人区一区二区三| 满18在线观看网站| 日韩有码中文字幕| 国产精品一区二区在线不卡| 国产在视频线精品| 激情视频va一区二区三区| 巨乳人妻的诱惑在线观看| 亚洲精品美女久久av网站| 久久久久久久久久久久大奶| 免费不卡黄色视频| 黄色怎么调成土黄色| 黄色视频在线播放观看不卡| 精品亚洲成a人片在线观看| 黄频高清免费视频| 国产一区二区在线观看av| 日本av手机在线免费观看| 欧美日韩av久久| 国产在线一区二区三区精| 精品乱码久久久久久99久播| 国产福利在线免费观看视频| 国产国语露脸激情在线看| 日本猛色少妇xxxxx猛交久久| 欧美日韩国产mv在线观看视频| 日韩中文字幕欧美一区二区| 无遮挡黄片免费观看| 亚洲成av片中文字幕在线观看| 亚洲精品中文字幕一二三四区 | 亚洲av欧美aⅴ国产| 熟女少妇亚洲综合色aaa.| 国产99久久九九免费精品| 亚洲色图综合在线观看| 国产麻豆69| 国产在线视频一区二区| av在线app专区| 免费日韩欧美在线观看| 婷婷丁香在线五月| 亚洲欧洲精品一区二区精品久久久| 亚洲av片天天在线观看| 女人被躁到高潮嗷嗷叫费观| a级片在线免费高清观看视频| 亚洲国产精品一区二区三区在线| 性少妇av在线| 啦啦啦在线免费观看视频4| 在线十欧美十亚洲十日本专区| 男人舔女人的私密视频| 国产欧美日韩精品亚洲av| 欧美日韩成人在线一区二区| 男女高潮啪啪啪动态图| 国产老妇伦熟女老妇高清| 波多野结衣av一区二区av| 国产在线免费精品| 免费观看a级毛片全部| 亚洲精品国产色婷婷电影| 欧美日韩av久久| 日本91视频免费播放| 黄色视频,在线免费观看| 一区在线观看完整版| 亚洲国产精品一区三区| 亚洲欧美精品综合一区二区三区| 天天影视国产精品| 亚洲精品中文字幕一二三四区 | 交换朋友夫妻互换小说| 成人国产av品久久久| 波多野结衣一区麻豆| 中文字幕最新亚洲高清| 久久久久久免费高清国产稀缺| 80岁老熟妇乱子伦牲交| 久久人妻福利社区极品人妻图片| 热99re8久久精品国产| 亚洲色图综合在线观看| 韩国高清视频一区二区三区| 欧美午夜高清在线| 久久久久国内视频| 久久久精品国产亚洲av高清涩受| 色视频在线一区二区三区| 又紧又爽又黄一区二区| 日韩电影二区| 男女下面插进去视频免费观看| 婷婷丁香在线五月| 五月天丁香电影| 午夜福利视频在线观看免费| 精品国产一区二区三区久久久樱花| 女警被强在线播放| 日本av手机在线免费观看| 一边摸一边做爽爽视频免费| 日韩欧美一区视频在线观看| 亚洲欧美精品自产自拍| 操美女的视频在线观看| 亚洲av成人一区二区三| 黑人巨大精品欧美一区二区蜜桃| 亚洲精品粉嫩美女一区| 成年人黄色毛片网站| 青青草视频在线视频观看| 亚洲五月色婷婷综合| 宅男免费午夜| 欧美日韩视频精品一区| 一级毛片精品| 久久精品aⅴ一区二区三区四区| 国产极品粉嫩免费观看在线| a级毛片黄视频| 国产一区二区激情短视频 | 我要看黄色一级片免费的| 国产在线一区二区三区精| 美女高潮到喷水免费观看| 亚洲人成电影观看| 欧美另类一区| 国产精品一区二区精品视频观看| 欧美黑人精品巨大| 欧美在线一区亚洲| 午夜激情久久久久久久| 美国免费a级毛片| 91字幕亚洲| 国产一区二区三区在线臀色熟女 | 亚洲精品国产精品久久久不卡| 精品熟女少妇八av免费久了| 国产视频一区二区在线看| 国产精品.久久久| svipshipincom国产片| 国产精品影院久久| 99香蕉大伊视频| 97人妻天天添夜夜摸| 黑丝袜美女国产一区| 国产成人av激情在线播放| 国产淫语在线视频| 亚洲成国产人片在线观看| 亚洲国产欧美日韩在线播放| 欧美日韩成人在线一区二区| 久久九九热精品免费| 水蜜桃什么品种好| 国产色视频综合| 欧美日韩亚洲高清精品| av片东京热男人的天堂| 精品国产一区二区三区四区第35| 欧美少妇被猛烈插入视频| 欧美老熟妇乱子伦牲交| 日日爽夜夜爽网站| 丝袜美腿诱惑在线| 黄色视频在线播放观看不卡| 成人手机av| 国产欧美日韩一区二区三区在线| 99热网站在线观看| 巨乳人妻的诱惑在线观看| 午夜成年电影在线免费观看| 欧美黑人欧美精品刺激| 午夜日韩欧美国产| 狠狠婷婷综合久久久久久88av| 午夜91福利影院| 可以免费在线观看a视频的电影网站| 亚洲精品在线美女| 91国产中文字幕| 亚洲中文日韩欧美视频| 午夜91福利影院| 考比视频在线观看| 我的亚洲天堂| 久久女婷五月综合色啪小说| 无限看片的www在线观看| 精品福利永久在线观看| 999久久久精品免费观看国产| 欧美日韩福利视频一区二区| 一个人免费看片子| 国产精品 欧美亚洲| 国产伦理片在线播放av一区| 午夜福利视频精品| 男女免费视频国产| av免费在线观看网站| 成人手机av| 日韩制服丝袜自拍偷拍| 自拍欧美九色日韩亚洲蝌蚪91| 久热这里只有精品99| 三级毛片av免费| 日本五十路高清| 老司机福利观看| 欧美av亚洲av综合av国产av| 女人精品久久久久毛片| 国产精品久久久av美女十八| 成人影院久久| 成人免费观看视频高清| 免费在线观看视频国产中文字幕亚洲 | 亚洲一码二码三码区别大吗| 国产亚洲一区二区精品| 极品人妻少妇av视频| 精品一区二区三卡| 青春草亚洲视频在线观看| 国产欧美日韩精品亚洲av| 99久久99久久久精品蜜桃| 国产福利在线免费观看视频| 热re99久久精品国产66热6| 人人妻人人澡人人看| 欧美精品高潮呻吟av久久| 精品一区在线观看国产| 国产三级黄色录像| 国产精品熟女久久久久浪| 亚洲一区二区三区欧美精品| 纯流量卡能插随身wifi吗| 一本—道久久a久久精品蜜桃钙片| 久久久精品免费免费高清| 国产一区二区 视频在线| 亚洲av日韩精品久久久久久密| 超碰成人久久| 91国产中文字幕| 国产在线一区二区三区精| 欧美另类亚洲清纯唯美| 精品人妻熟女毛片av久久网站| 亚洲成人手机| 老鸭窝网址在线观看| 丝袜在线中文字幕| 亚洲免费av在线视频| 国产主播在线观看一区二区| 亚洲色图综合在线观看| 日本a在线网址| 建设人人有责人人尽责人人享有的| 国产国语露脸激情在线看| 美女午夜性视频免费| 制服人妻中文乱码| 天天添夜夜摸| 九色亚洲精品在线播放| 国产极品粉嫩免费观看在线| 日韩电影二区| 精品一区二区三区av网在线观看 | 久久久久久久久久久久大奶| 女人被躁到高潮嗷嗷叫费观| 国产男人的电影天堂91| 亚洲第一青青草原| 亚洲国产欧美网| 国产精品 国内视频| 中文字幕制服av| 中文精品一卡2卡3卡4更新| 人人妻人人爽人人添夜夜欢视频| 国产亚洲精品一区二区www | tube8黄色片| 亚洲欧洲精品一区二区精品久久久| 国产精品九九99| 热99国产精品久久久久久7| 免费人妻精品一区二区三区视频| 女人高潮潮喷娇喘18禁视频| 成人影院久久| 99精国产麻豆久久婷婷| 日韩一区二区三区影片| 亚洲av男天堂| 精品乱码久久久久久99久播| 午夜福利影视在线免费观看| 大香蕉久久成人网| 免费黄频网站在线观看国产| 亚洲情色 制服丝袜| 丝袜美腿诱惑在线| 一区二区三区激情视频| 成人国语在线视频| 欧美激情 高清一区二区三区| 黑人操中国人逼视频| 男女边摸边吃奶| 久久人人97超碰香蕉20202| 国产成人啪精品午夜网站| 美女高潮到喷水免费观看| 下体分泌物呈黄色| 国产成人av教育| 久久久精品免费免费高清| 国产av国产精品国产| 国产成人精品无人区| 国产高清视频在线播放一区 | 91精品三级在线观看| 免费在线观看视频国产中文字幕亚洲 | 在线观看免费高清a一片| 欧美精品人与动牲交sv欧美| 男人舔女人的私密视频| 国产精品 欧美亚洲| 90打野战视频偷拍视频| 黑人巨大精品欧美一区二区mp4| 菩萨蛮人人尽说江南好唐韦庄| 国产免费av片在线观看野外av| 丝袜美足系列| 国产成人影院久久av| 精品亚洲乱码少妇综合久久| 中国国产av一级| 日韩欧美免费精品| 国产精品久久久久久精品古装| 91麻豆av在线| 国产精品九九99| 九色亚洲精品在线播放| 性少妇av在线| 人妻一区二区av| 两性午夜刺激爽爽歪歪视频在线观看 | 男人爽女人下面视频在线观看| av福利片在线| 久久久精品免费免费高清| 精品卡一卡二卡四卡免费| 亚洲人成电影观看| av在线老鸭窝| 精品国内亚洲2022精品成人 | 久久久精品免费免费高清| 99久久综合免费| 免费高清在线观看视频在线观看| 天天躁狠狠躁夜夜躁狠狠躁| 色视频在线一区二区三区| 大型av网站在线播放| 自线自在国产av| av天堂久久9| 欧美日韩亚洲综合一区二区三区_| 亚洲精品在线美女| 一级片'在线观看视频| 久久久国产精品麻豆| 一边摸一边做爽爽视频免费| 少妇的丰满在线观看| 19禁男女啪啪无遮挡网站| 国产精品1区2区在线观看. | 欧美激情高清一区二区三区| 国产一级毛片在线| 国产精品欧美亚洲77777| 最近中文字幕2019免费版| 婷婷成人精品国产| 夫妻午夜视频| 美女脱内裤让男人舔精品视频| 蜜桃国产av成人99| √禁漫天堂资源中文www| 99国产综合亚洲精品| 亚洲精品国产区一区二| 日本猛色少妇xxxxx猛交久久| 老司机影院毛片| 国产精品一二三区在线看| 老司机福利观看| 国产精品一区二区在线观看99| 国产精品一二三区在线看| 一级片'在线观看视频| 国产精品一区二区在线观看99| 韩国高清视频一区二区三区| 一级片'在线观看视频| 老司机影院毛片| 老汉色∧v一级毛片| 黑人猛操日本美女一级片| 国产精品自产拍在线观看55亚洲 | 97精品久久久久久久久久精品| 一本—道久久a久久精品蜜桃钙片| 十八禁网站网址无遮挡| 无限看片的www在线观看|